Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study.

Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Abstract Text:

A V Krymchantowski,J S Barbosa,

Rizatriptan is an effective and fast acting drug for the acute treatment of migraine. As with any other acute treatment for migraine, headache recurrence may occur in up to one-third of responders. Combination with non-steroidal anti-inflammatory drugs (NSAIDs) seems to reduce the incidence of headache recurrence in clinical practice. Rofecoxib is a member of a new class of NSAIDs, which selectively inhibits the COX-2 enzyme and therefore is associated with a lower risk of gastrointestinal side-effects; the drug has a long plasma half-life (17 h). This open label study compared rizatriptan with rizatriptan plus rofecoxib in the acute treatment of migraine. Fifty-six triptan naive patients from a tertiary centre (37 women and 19 men, ages 16-55 years, mean 35 years) with International Headache Society migraine were randomized into two groups. They were instructed to treat three consecutive moderate or severe attacks with either 10 mg rizatriptan (group 1: 18 women and 10 men) or with 10 mg rizatriptan plus 25 mg rofecoxib (group 2: 19 women and 9 men). The presence of headache and nausea at 1, 2 and 4 h, and of side-effects, use of rescue medication and recurrence were compared. Fifty-four patients completed the study. Group 1 treated 76 attacks and group 2 treated 81 attacks. Absence of headache at 1 h was seen in 19 attacks (25%) in group 1 and in 34 attacks (42%) in group 2 (P=0.082); at 2 h absence of headache was seen in 60% of group 1 attacks and in 76% of group 2 attacks (P=0.115). At 4 h, 75% of group 1 attacks and 88% of group 2 attacks were pain free (P=0.122). With regard to nausea, of those who had nausea at baseline, 31% and 49% of attacks in groups 1 and 2, respectively, were nausea free at 1 h (P=0.091), 75% and 79% at 2 h (P=0.736) and 82% and 91% (P=0.479) at 4 h. Recurrence, based on all attacks of those patients who achieved pain free at 4 h, was observed in 53% of group 1 and 20% of group 2 attacks (P<0.001). Sustained pain-free rates (for the 4-h time point) were 45.6% of group 1 and 78.9% of group 2 attacks. There were no significant differences with regard to rescue medication consumption after 4 h and side-effects in both groups. There was a non-significant trend for the combination group to have a higher response rate. The group treated with rizatriptan and rofecoxib had a lower recurrence rate than the group treated with rizatriptan. This study demonstrated that combining a fast acting triptan such as rizatriptan with rofecoxib reduced headache recurrence rates, was well tolerated and may be more effective than the use of rizatriptan alone. Double-blind, placebo-controlled studies are necessary to confirm these observations.

Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Publishing Authors By Initials

AV Krymchantowski,JS Barbosa,

For similar organic chemicals: amines: biogenic amines: biogenic monoamines: tryptamines research abstracts see: organic chemicals: amines: biogenic amines: biogenic monoamines: tryptamines research

PUBMED ID PMID:

MEDLINE DATE:

Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Journal Published:

PUBLICATION TYPE: Randomized Controlled Trial

Journal: Cephalalgia : an international journal of headache

VOLUME: 22

Page Numbers: 309-12

Journal Abbreviation: Cephalalgia

ISSN: 0333-1024

DAY: 11

MONTH: May

YEAR: 2002

Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8200710

Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Keywords Mesh Terms:

KEYWORDS: Tryptamines

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Information

Substance Name: rizatriptan

Registry Number: 145202-66-0

Grant and Affiliation Information for Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study.

AFFILIATION: Rio Military Police, Department of Neurology, Universidade Federal Fluminense, Headache Center of Rio, Rio de Janeiro, Brazil. abouchkrym@globo.com

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Cephalalgia

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Rizatriptan combined with rofecoxib vs rizatriptan for the acute treatment of migraine: an open label pilot study Related Publications

• Abdominal wall healing in reoperated rats.
• Adult T-cell leukemia/lymphoma in Bahia, Brazil: analysis of prognostic factors in a group of 70 patients.
• Analysis of opioid peptides by on-line SPE-CE-ESI-MS.
• Association between Helicobacter pylori concentration and the combining frequency of histopathological findings in gastric biopsies specimens.
• Characterization and treatment of artisanal gold mine tailings.
• Diagnostic pitfalls in Parkinson's disease: case report.
• Effects of gamma-irradiation on the membrane ATPases of human erythrocytes from transfusional blood concentrates.
• Histological comparison of demineralized bone matrix and the Ricinus communis polymer on bone regeneration.
• Osteoblast adhesion and morphology on TiO(2) depends on the competitive preadsorption of albumin and fibronectin.
• Prednisone as initial treatment of analgesic-induced daily headache.
• Prevalence and associated risk factors for Giardia lamblia infection among children hospitalized for diarrhea in Goiânia, Goiás State, Brazil.
• Quasi-elastic light scattering of Carnauba wax in the liquid phase: dynamics 1.
• Quasi-elastic light scattering of carnauba wax in the liquid phase: dynamics 2.
• Quasi-stationary multiple stimulated Raman generation in the visible using optical fibers.
• Relationship between Candida and nocturnal denture wear: quantitative study.
• Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study.
• The crystal structure of a lysozyme c from housefly Musca domestica, the first structure of a digestive lysozyme.
• The presence of Helicobacter pylori in postmenopausal women is not a factor to the decrease of bone mineral density.
• Toward the development of a general chiral auxiliary. A total synthesis of (+)-tetronolide via a tandem ketene-trapping [4 + 2] cycloaddition strategy.
• Transcutaneous bilirubinometry: important method in the evaluation of newborns with hyperbilirubinemia.
• [Evaluation of the coverage of the vaccine against yellow fever in Boa Vista, Federal Territory of Roraima]
• [Frequency of Gardnerella vaginalis in vaginal smears of hysterectomized women]
• [NEW THERAPEUTIC TRIALS OF THIOPROPERAZINE (RP 7843) IN PSYCHIATRY.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Portuguese hospitals.]
• [Schistosomiasis in area of the Distrito Federal. Preliminary note]
• [Schistosomiasis morbidity]
• [Subjective visual vertical evaluation in normal Brazilian subjects]